Skip to content
Screener

Immunovant, Inc. IMVT Q1 2026 earnings

Reported August 11, 2025 · Before market open

EPS-$0.60Beat by $0.09
EPS estimate-$0.69

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$7.1M
EPS estimate-$0.73

Financials

Q1 2026

Income statement

See full
Net income-$120.6M-38.4%
EPS (diluted)-$0.71-18.3%

Balance sheet

See full
Cash & equivalents$598.9M+6.9%
Total equity$608.5M+11.7%
Total assets$661.4M+12.2%

Cash flow

See full
Operating cash flow-$117.4M-54.1%
CapEx--100%
Free cash flow-$117.4M-53.7%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$2.73B-28.7%

Returns & leverage

See full
Return on equity-77.6%+19.6pp
Current ratio12.3×-0.8×

FAQ

When did Immunovant, Inc. report Q1 2026 earnings?
Immunovant, Inc. (IMVT) reported Q1 2026 earnings on August 11, 2025 before market open.
What were Immunovant, Inc.'s Q1 2026 revenue and EPS?
Immunovant, Inc. reported eps of $-0.60 for Q1 2026.
Did Immunovant, Inc. beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.69 by $0.09.
How did Immunovant, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 0.0% from $-0.60.
Where can I find Immunovant, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001764013-25-000128) and the 10-Q periodic report (0001764013-25-000129) directly on SEC EDGAR. The filing index links above go to sec.gov.